Transition to glycerol phenylbutyrate for the management of urea cycle disorders: clinical experiences

M. Sacchini, E. Procopio, F. Pochiero, G. Scaturro, M. Daniotti, M.A. Donati

Metabolic and Muscular Unit Disease, AOU-IRCCS Meyer Children Hospital, Florence, Italy. michele.sacchini@meyer.it

---

• Urology

BACKGROUND: Urea cycle disorders (UCDs) are a group of rare inborn diseases caused by a deficiency in one of the six enzymes or one of the two transporters involved in the urea cycle. The most common biochemical feature is elevated blood ammonia levels, which can be toxic at high levels, especially to the brain and may manifest as encephalopathy if left untreated. Glycerol phenylbutyrate (GPB) is currently approved for use in the USA and Europe for patients of all ages with UCD who cannot be managed with protein restriction and/or amino acid supplementation alone. This article presents the author’s experience in different exemplary settings and depicts the most efficient management of UCDs with GPB.

CASE PRESENTATION: Six patient histories are described. 4 had OCT, one citrullinemia, and one argininosuccinic aciduria. Treatment with GPB was started between 2 days and 14 years of age. Before GPB, one patient had not been treated, 4 had received sodium phenylbutyrate (NaPB), and one Na benzoate.

CONCLUSIONS: Overall, treatment with GPB was followed by a relevant metabolic improvement, resulting in better therapeutic compliance, reduced hospitalization, and improved quality of life.

Free PDF Download